Skip to main content
. 2015 Jan 23;9(4):312–317. doi: 10.1093/ecco-jcc/jjv027

Table 1.

Patient characteristics.

Characteristics Total [n=73]a Responderd [n=46]a Non-responder [n=27]a p Valuec
Age at MTX initiation [years]d 30 [14-67] 28 [14-65] 35 [15-52] 0.57
Median duration of disease at MTX initiation [years]d 5 [0-43] 5 [0-32] 5 [2-43] 0.93
Median duration of MTX use [months]d 17 [0-112] 17 [2-112] 6 [0-18] 0.91
Male sex 50 [69%] 34 [74%] 16 [59%] 0.30
Smokers, former smokers 7 [10%], 9 [12%] 6 [13%], 5 [11%] 1 [46%], 4 [15%] 0.25; 0.72
Crohn’s disease 54 [74%] 35 [76%] 19 [70%] 0.79
Age at diagnosis [years] [A1, A2, A3]e 18 [33%], 31 [57%] 5 [9%] 12 [34%], 20 [57%], 3 [9%] 6 [32%], 11 [58%], 2 [11%] 0.78; 0.82; 1.00
Location [L1, L2, L3]f 10 [18%], 8 [15%], 36 [67%] 7 [20%], 3 [9%], 25 [71%] 3 [16%], 5 [26%], 11 [58%] 0.74; 0.14; 0.38
Addition of L4f 11 [20%] 7 [20%] 4 [21%] 1.00
Crohn’s disease
Behavior [B1, B2, B3]g 18 [33%], 15 [28%] 21 [39%] 12 [34%], 9 [36%] 14 [40%] 6 [32%], 6 [32%] 7 [37%] 0.93; 0.79; 0.89
Perianal disease 19 [35%] 13 [37%] 6 [32%] 0.77
Ulcerative colitis 16 [22%] 8 [17%] 8 [30%] 0.36
Extent
- Left-sided 6 [38%] 3 [38%] 3 [38%] 0.66
- Extensive 10 [62%] 5 [63%] 5 [63%] 0.57
Indeterminate colitis 3 [4%] 3 [7%] 0 0.29
Low-dose MTXh 51 [71%] 32 [70%] 19 [70%] 0.94
Oral MTX route 55 [75%] 35 [76%] 20 [74%] 0.85
Concomitant anti-TNF agent
- Adalimumab 36 [49%] 24 [52%] 12 [44%] 0.56
- Infliximab 29 [40%] 20 [43%] 9 [33%] 0.54
- Certolizumab pegol 8 [11%] 2 [4%] 6 [22%] 0.05

MTX, methotrexate; anti-TNF, anti tumor necrosis factor.

a% relates to the total n per column.

bResponder, achieved remission after induction of MTX therapy.

cLow dose equals ≤ 12.5 mg.

dAge and duration are expressed as median [range].

eA1 <16 years; A2 17-49 years; A3 >40 years.

fL1 ileal; L2 colonic; L3 ileocolonic; L4 upper GI.

gB1 non-stricturing, non-penetrating; B2 stricturing; B3 penetrating.

hCalculated for responders versus non-responders.